PUBLISHER: The Business Research Company | PRODUCT CODE: 1658848
PUBLISHER: The Business Research Company | PRODUCT CODE: 1658848
Bio-implants are sophisticated medical devices or prostheses crafted from materials sourced from human or animal origin, as well as biosynthetic materials. These implants serve the crucial function of replacing missing tissues and supporting damaged biological structures, ultimately enhancing the body's biological functions. Bio-implants are instrumental in assisting and regulating various human physiological functions.
Within the bio-implant category, there are several main types, including cardiovascular implants, dental implants, spinal bio-implants, orthopedic implants, ophthalmic implants, and others. Cardiovascular implants, such as heart valves and coronary stents, play a vital role in treating cardiac complications, designed to remain within a patient's body to support healthy blood arteries and a functioning heart. Bio-implants are crafted from diverse materials, including metallic, ceramic, polymer, and biological components. They originate from different sources such as allograft, autograft, xenograft, and synthetic materials. These bio-implants find application in various healthcare settings, including ambulatory surgical centers, clinics, hospitals, and other end-user facilities.
The bio-implants market research report is one of a series of new reports from The Business Research Company that provides bio-implants market statistics, including bio-implants industry global market size, regional shares, competitors with a bio-implants market share, detailed bio-implants market segments, market trends and opportunities, and any further data you may need to thrive in the bio-implants industry. This bio-implants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The bio-implants market size has grown strongly in recent years. It will grow from $125.48 billion in 2024 to $137.99 billion in 2025 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to aging population and chronic diseases, rise in surgical procedures, increased life expectancy, regulatory support and standards.
The bio-implants market size is expected to see rapid growth in the next few years. It will grow to $210.36 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to customization and personalization, growth in minimally invasive procedures, shift towards regenerative medicine, remote monitoring and telemedicine, supportive regulatory environment. Major trends in the forecast period include customized and personalized implants, biodegradable and bioresorbable implants, advancements in biomaterials, regenerative medicine and tissue engineering, smart implants and wearable technologies.
The rising prevalence of chronic conditions is anticipated to drive growth in the bio-implant market in the coming years. Chronic conditions, including cardiovascular diseases and arthritis, are defined as medical issues that persist for a year or longer, necessitate ongoing medical care, and limit daily activities. Bio-implants play a crucial role in managing and monitoring these chronic conditions, contributing to a reduction in mortality rates associated with such diseases. For instance, in July 2024, the Australian Institute of Health and Welfare reported that chronic obstructive pulmonary disease (COPD) was responsible for 7,691 deaths in Australia in 2022, equating to 29.6 deaths per 100,000 people and accounting for 4.0% of all fatalities. Therefore, the increasing prevalence of chronic conditions is propelling the growth of the bio-implant market.
The bio-implants market is experiencing growth attributed to the aging population, characterized by an increasing proportion of elderly individuals in societies. Bio implants serve diverse purposes, including real-time health monitoring, drug delivery, and tissue regeneration, catering to age-related health issues. The World Health Organization's October 2022 projections indicate a significant demographic shift, with one in six individuals globally expected to be 60 years or older by 2030. This demographic transition, marked by a rise from 1 billion in 2020 to 1.4 billion individuals aged 60 and over, is a clear indication of the increasing demand for bio-implants. Looking ahead to 2050, the global population of individuals aged 60 and older is projected to double to 2.1 billion. The aging population is thus a significant driver for the expanding bio-implants market.
In the bio-implant market, key trends are centered around technological advancements, with major players focusing on innovative biomaterial technology, particularly 3D printing for bio-implant systems. This additive manufacturing technique produces 3D structures using cells and biomaterials, deviating from traditional metals and polymers. A notable example is the March 2022 launch of Evonik Industries AG's osteoconductive VESTAKEEP iC4800 3DF PEEK filament. This high-performance polymer, based on 3D-printing technology, enhances osteointegration between bone and implant, expediting bone healing. Notable features include impressive biocompatibility, biostability, and enhanced osteoconductive qualities, reflecting the forefront of technical innovation in the bio-implant sector.
Major companies in the bio-implants market are actively introducing novel implant solutions to elevate patient care standards. Notably, the introduction of the REGENETEN Bioinductive Implant by Smith+Nephew in July 2023 stands out. This collagen-based implant supports the body's natural healing response, fostering the growth of new tendon-like tissue to reinforce existing tendons. Launched in India after completing over 100,000 global procedures, this arthroscopically delivered implant has demonstrated promising results in rotator cuff disease. Clinical trials have shown an 86% relative reduction in re-tear rates at 12 months compared to conventional surgery alone, positioning the REGENETEN Bioinductive Implant as a transformative advancement in bio-implant technology.
In August 2022, CONMED Corporation, a prominent US-based medical technology company, made a strategic move by acquiring Biorez Inc., a medical device start-up, for an undisclosed amount. This acquisition is poised to enhance CONMED's sports medicine portfolio, with the addition of Biorez bringing innovative capabilities to the forefront. The acquisition strategically positions CONMED to capitalize on emerging technologies and reinforces its commitment to growth and innovation in the competitive bio-implant market.
Major companies operating in the bio-implants market are Medtronic PLC, Stryker Corporation, Zimmer Biomet Holdings Inc., Dentsply Sirona Inc., Johnson & Johnson, Arthrex Inc., Boston Scientific Corporation, Smith & Nephew PLC, B. Braun Melsungen AG, Victrex PLC, Straumann Holding AG, Danaher Corporation, Cardinal Health Inc., Organogenesis Holdings Inc., Exactech Inc., Osprey Medical Inc., Edwards Lifesciences Corporation, Biotronik SE & Co. KG, aap Implantate AG, Abbott Laboratories, Biotronik Inc., Cook Medical LLC, Globus Medical Inc., Integra LifeSciences Holdings Corporation, LivaNova PLC, MicroPort Scientific Corporation, NuVasive Inc., Orthofix Medical Inc., RTI Surgical Holdings Inc., Terumo Corporation
North America was the largest region in the bio-implants market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bio-implants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the bio-implants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The bio implants market consists of sales stents, pacing devices, orthobiologics, trauma implants, sport medicines, thoracolumber implants, intervertebral spacers, machined allograft spacers, and motion preservation implants. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Bio-Implants Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on bio-implants market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for bio-implants ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The bio-implants market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.